Dotarizin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dotarizin" in Serbian language version.

refsWebsite

Global rank Serbian rank

8nih.gov

4^th place

8^th place

4doi.org

2^nd place

4^th place

1archive.org

6^th place

5^th place

archive.org

Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences. 175 (1): 13—6. PMID 10785251. doi:10.1016/S0022-510X(00)00275-6.

doi.org

Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”. European Journal of Pharmacology. 411 (3): 289—99. PMID 11164387. doi:10.1016/S0014-2999(00)00897-9.
Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”. European Journal of Pharmacology. 481 (1): 41—50. PMID 14637173. doi:10.1016/j.ejphar.2003.09.013.
Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology. 332 (2): 183—93. PMID 9286620. doi:10.1016/S0014-2999(97)01073-X.
Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences. 175 (1): 13—6. PMID 10785251. doi:10.1016/S0022-510X(00)00275-6.

nih.gov

ncbi.nlm.nih.gov

Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”. European Journal of Pharmacology. 411 (3): 289—99. PMID 11164387. doi:10.1016/S0014-2999(00)00897-9.
Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”. European Journal of Pharmacology. 481 (1): 41—50. PMID 14637173. doi:10.1016/j.ejphar.2003.09.013.
Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”. Methods and findings in experimental and clinical pharmacology. 19 (5): 343—50. PMID 9379783.
Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology. 332 (2): 183—93. PMID 9286620. doi:10.1016/S0014-2999(97)01073-X.
Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia”. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 36 (2): 101—8. PMID 9757621.
Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences. 175 (1): 13—6. PMID 10785251. doi:10.1016/S0022-510X(00)00275-6.
Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug”. Methods and findings in experimental and clinical pharmacology. 17 (10): 659—68. PMID 9053586.
Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats”. Methods and findings in experimental and clinical pharmacology. 17 (1): 53—8. PMID 7623521.